Abstracts tagged "Diagnostic Tests"

Abstract Number: 405 • 2015 ACR/ARHP Annual Meeting
Anti-C1q Antibodies As Potential Diagnostic and Prognostic Biomarkers in Juvenile Systemic Lupus Erythematosus
Thaschawee Arkachaisri^1,2, Justin Hung Tiong Tan¹, Manasita Tanya¹, Sook Fun Hoh³, Lena Das⁴ and Jing Yao Leong^5,6, ¹Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Paediatrics, Duke-NUS Graduate Medical School, Singapore, Singapore, ³Nursing, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Dept of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ⁵Duke-National University of Singapore Graduate Medical School, Singapore, Singapore, ⁶SingHealth Translational Immunology and Inflammation Centre, Singapore Health Services Pte Ltd, Singapore, Singapore
Background/Purpose: Anti-C1q antibodies (AC1q) were shown to strongly correlate with the occurrence and activity of lupus nephritis in adult SLE. Data of the antibodies in…
Abstract Number: 2695 • 2015 ACR/ARHP Annual Meeting
Th17 Cell Related Cytokines and Microarray Expression Profiles in Patients with Early Rheumatoid Arthritis
Youngkyun Kim¹, Kijun Lee², Hae-Rim Kim³, Sang Heon Lee⁴, Ji Hyeon Ju⁵ and HO-YOUN KIM⁶, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²The Catholic University of Korea, Seoul, South Korea, ³Konkuk University Medical Center, Seoul, South Korea, ⁴Konkuk University Hospital, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Konkuk university hospital, Seoul, South Korea
Background/Purpose: The purpose of this study is to explore new biomarkers for early diagnosis of rheumatoid arthritis (RA). For better discrimination power, we especially investigated…
Abstract Number: 765 • 2015 ACR/ARHP Annual Meeting
Clinical Improvements in Systemic Lupus Erthematosus Are Correlated to Cellular and Soluble Biomarkers in Classical Complement Pathway
Chaim Putterman¹, Jill P. Buyon², Richard Furie³, Rosalind Ramsey-Goldman⁴, Kenneth Kalunian⁵, John Conklin⁶, Tyler O'Malley⁷, Derren Barken⁸ and Thierry Dervieux⁷, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²NYU School of Medicine, New York, NY, ³NSLIJHS, Lake Success, NM, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵UCSD School of Medicine, La Jolla, CA, ⁶1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁷Research and Development, Exagen Diagnostics, Vista, CA, ⁸Exagen Diagnostics, Vista, CA
Background/Purpose : There is a need to identify biomarkers that track disease response in systemic lupus erythematosus (SLE). The value of various biomarkers in monitoring…
Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting
Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?
Ryota Sakai¹, Akiko Shibata¹, Kentaro Chino¹, Jun Kikuchi², Tsuneo Kondo¹, Ayumi Okuyama¹, Hirofumi Takei¹ and Koichi Amano¹, ¹Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ²Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan
Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
Abstract Number: 767 • 2015 ACR/ARHP Annual Meeting
Estimating the Pre-Test Probability of Systemic Lupus Erythematosus By Utilizing Anti-Double Stranded DNA and Cell Bound Complement Activation Products Testing from Rheumatology Based Practices in the United States
Stuart L. Silverman¹, Derren Barken², John Conklin³, Claudia Ibarra⁴ and Thierry Dervieux⁵, ¹OMC Clinical Research Center, Beverly Hills, CA, ²Exagen Diagnostics, Vista, CA, ³1261 Liberty Way Suite C, Exagen Diagnostics, Vista, CA, ⁴Clinical Laboratory, Exagen Diagnostics, Vista, CA, ⁵Research and Development, Exagen Diagnostics, Vista, CA
Background/Purpose : Clinicians are aware that the interpretation of any clinical diagnostic test and post-test probability of disease is highly influenced by pre-test probability or…
Abstract Number: 2944 • 2015 ACR/ARHP Annual Meeting
Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Kohei Tsujimoto¹, Masaaki Fujita², Yutaka Shinkawa², Iku Shirasugi¹, Masashi Taniguchi¹, Saori Hatachi³ and Masato Yagita⁴, ¹Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ²Department of Clinical Immunology and Rheumatology C, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ³Department of Rheumatology, Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan, ⁴Tazuke Kofukai Foundation, Medical Research Institute, Kitano Hospital, Osaka, Japan
Background/Purpose: Presepsin (sCD14 subtype) has recently been identified as a novel biomarker for predicting sepsis. Because presepsin is produced as a consequence of cellular phagocytosis,…
Abstract Number: 776 • 2015 ACR/ARHP Annual Meeting
Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Ivan Alcantara-Arreola¹, Nina Tello-Winniczuk² and Alejandro Diaz-Borjon³, ¹Hospital Angeles Lomas, Huixquilucan, Mexico, ²Division of Internal Medicine / Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico, ³Med/Div of Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico
Background/Purpose: A positive ANA test is a diagnostic criterion for several rheumatic diseases, although it may appear in other autoimmune disorders and healthy individuals. An…
Abstract Number: 2961 • 2015 ACR/ARHP Annual Meeting
Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Veronica J. Berrocal², Gandikota Girish³, Meng Zhang⁴, Chris Hatzis¹, Shervin Assassi⁵, Elana J. Bernstein⁶, Robyn T. Domsic⁷, Faye N. Hant⁸, Monique E. Hinchcliff⁹, Elena Schiopu¹⁰, Virginia D. Steen¹¹, Tracy M. Frech¹² and Dinesh Khanna¹³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Div of Rheumatology, University of Michigan, Ann Arbor, MI, ³Radiology, University of Michigan, Ann Arbor, MI, ⁴Epidemiology and Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁶Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ⁷Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Dept of Medicine, Medical University of South Carolina, Charleston, SC, ⁹Division of Rheumatology, Division of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, ¹⁰University of Michigan, Ann Arbor, MI, ¹¹Rheumatology, Georgetown University Medical Center, Washington, DC, ¹²Div of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Arthropathy and tendinopathy in Systemic Sclerosis (SSc) contribute to disability and are associated with disease progression. Clinical trials in SSc sometimes include the tender…
Abstract Number: 777 • 2015 ACR/ARHP Annual Meeting
SLE-KeyTM Rule-out Test to Assess Lupus in Anti-Nuclear Antibody Positive Subjects Using the Immunarray iCHIP®
D. Scott Batty¹, I.R. Cohen², Chaim Putterman³, Nicole Jordan⁴, Keren Jakobi⁵, Rachel Sorek⁵, Yakov Blumenstein⁵, Pennina Safer⁵ and David Pisetsky⁶, ¹ImmunArray Inc., Richmond, VA, ²Weizmann Institute of Science, Rehovot, Israel, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel, ⁶Duke University Medical Center and Durham VAMC, Durham, NC
Background/Purpose: SLE is associated with a broad spectrum of autoantibodies, but currently there is no single serologic test to diagnose SLE definitively. Diagnosis is thus…
Abstract Number: 3127 • 2015 ACR/ARHP Annual Meeting
Serologic Diagnosis of Human Neuropsychiatric Lupus Using the Immunarray ICHIP®
Chaim Putterman¹, D. Scott Batty², I.R. Cohen³, Nicole Jordan⁴, Debbie Rybak¹, Tamar Rubinstein¹, Keren Jakobi⁵, Rachel Sorek⁵, Anat Reiner-Benaim⁵, Yakov Blumenstein⁵ and Pennina Safer⁵, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, ²ImmunArray Inc., Richmond, VA, ³Weizmann Institute of Science, Rehovot, Israel, ⁴Montefiore Medical Center, New York, NY, ⁵ImmunArray LTD, Rehovot, Israel
Background/Purpose: Peripheral neurologic syndromes and central nervous system (CNS) manifestations are recognized as primary disease manifestations in systemic lupus erythematosus (SLE). Neuropsychiatric SLE (NPSLE) involves…
Abstract Number: 1095 • 2015 ACR/ARHP Annual Meeting
Identification of Carbamylated Alpha-1-Anti-Trypsin (A1AT) As an Antigenic Target of Anti-Carp Antibodies in Patients with Rheumatoid Arthritis
Marije K. Verheul¹, Alvin Yea², Andrea Seaman², Robert A. Cordfunke³, Jan W. Drijfhout⁴, George M. Janssen⁴, Arnoud de Ru³, Peter A. van Veelen⁴, René E. M. Toes⁵, Michael Mahler² and Leendert A. Trouw¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Inova Diagnostics, San Diego, CA, ³IHB, Leiden University Medical Center, Leiden, Netherlands, ⁴Immunohematology and Bloodbank, Leiden University Medical Center, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Antibodies targeting carbamylated proteins (anti-CarP) were recently identified in serum samples from patients with rheumatoid arthritis (RA). The presence of anti-CarP antibodies was associated…
Abstract Number: 1354 • 2015 ACR/ARHP Annual Meeting
Whipple’s Disease: The Diagnostic Utility of Synovial Fluid Tropheryma Whipplei Polymerase Chain Reaction
Zoran Kvrgic¹, Kelly Cawcutt², Robin Patel³, Abinash Virk², Clement J. Michet Jr.⁴, Eric L. Matteson⁵ and Tim Bongartz¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Infectious Diseases, Mayo Clinic, Rochester, MN, ³Medicine, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN, ⁵Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: Inflammatory arthritis is a common, non-specific symptom of Whipple’s disease. Recovery of the organism by conventional culture is often unsuccessful. Synovial fluid polymerase chain…
Abstract Number: 1714 • 2015 ACR/ARHP Annual Meeting
Young Patients with Back Pain and Maximally 1 Spa Feature: Is It Useful to Test HLA-B27 or Image the Sacroiliac Joints?
Pauline Bakker¹, Zineb Ez-Zaitouni², Miranda van Lunteren², Manouk de Hooge³, Rosaline van den Berg⁴, Inger Jorid Berg⁵, Robert B. M. Landewé⁶, Maikel van Oosterhout⁷, Roberta Ramonda⁸, Monique Reijnierse⁹, Floris van Gaalen¹ and Désirée van der Heijde¹⁰, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Rheumatology, Leiden University Medical Centre, Leiden, Netherlands, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁶Rheumatology, University Hospital Maastricht, Maastricht, Netherlands, ⁷Rheumatology, GHZ Hospital, Gouda, Netherlands, ⁸Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁹Radiology, Leiden University Medical Center, Leiden, Netherlands, ¹⁰University Hospital, Maastricht, Netherlands
Background/Purpose: Axial SpondyloArthritis (axSpA) is a heterogeneous disease. The likelihood of diagnosis varies depending upon the specific findings that are present. However, it is debated…
Abstract Number: 1916 • 2015 ACR/ARHP Annual Meeting
Validation of Novel Biomarker Candidates for Systemic Sclerosis
Johannes Schulte-Pelkum¹, Petra Budde¹, Hans-Dieter Zucht¹, Daniel Wirtz¹, Peter Schulz-Knappe¹, Oliver Distler², Suzana Jordan³, Nicolas Hunzelmann⁴, Matthias Schneider⁵ and Britta Maurer², ¹Protagen AG, Dortmund, Germany, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany, ⁵Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. SSc is associated with the…
Abstract Number: 2065 • 2015 ACR/ARHP Annual Meeting
Verification of Novel Soluble Biomarkers That Differentiate Patients with Psoriatic Arthritis from Those with Psoriasis without Psoriatic Arthritis
Vinod Chandran¹, Daniela Cretu^2,3, Lisa Gao⁴, Kun Liang⁴, Antoninus Soosaipillai³ and Eleftherios Diamandis^2,3,5, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada, ³Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada
Background/Purpose: There is a high prevalence of undiagnosed psoriatic arthritis (PsA) in psoriasis patients. Therefore identifying soluble biomarkers for PsA will help in screening psoriasis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].